BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22946880)

  • 1. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.
    Kennedy NA; Asser TL; Mountifield RE; Doogue MP; Andrews JM; Bampton PA
    Intern Med J; 2013 Mar; 43(3):278-86. PubMed ID: 22946880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
    Nguyen TV; Vu DH; Nguyen TM; Lachaux A; Boulieu R
    Ther Drug Monit; 2013 Apr; 35(2):251-7. PubMed ID: 23503453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.
    Dewit O
    Acta Gastroenterol Belg; 2010; 73(3):331-5. PubMed ID: 21086934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L; Friedman AB; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.
    Waljee AK; Joyce JC; Wang S; Saxena A; Hart M; Zhu J; Higgins PD
    Clin Gastroenterol Hepatol; 2010 Feb; 8(2):143-50. PubMed ID: 19835986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC; Muktar H; Effken C; Mahajan PB
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I; Rentsch KM; Frei P; Fried M; Rogler G; Kullak-Ublick GA; Jetter A
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
    Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
    J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S; Vikingsson S; Söderman J; Hindorf U; Grännö C; Danelius M; Coulthard S; Peterson C; Almer S
    Ther Drug Monit; 2011 Apr; 33(2):200-8. PubMed ID: 21311411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
    Banerjee S; Bishop WP
    J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.